- Home
- AHG vs RIGL Comparison
AHG vs RIGL Comparison
Compare AHG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- RIGL
- Stock Information
- Founded
- AHG 2013
- RIGL 1996
- Country
- AHG China
- RIGL United States
- Employees
- AHG N/A
- RIGL N/A
- Industry
- AHG Business Services
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- RIGL Health Care
- Exchange
- AHG Nasdaq
- RIGL Nasdaq
- Market Cap
- AHG 245.7M
- RIGL 247.1M
- IPO Year
- AHG N/A
- RIGL 2000
- Fundamental
- Price
- AHG $0.92
- RIGL $25.03
- Analyst Decision
- AHG
- RIGL Buy
- Analyst Count
- AHG 0
- RIGL 5
- Target Price
- AHG N/A
- RIGL $31.30
- AVG Volume (30 Days)
- AHG 19.5K
- RIGL 285.9K
- Earning Date
- AHG 11-29-2024
- RIGL 11-07-2024
- Dividend Yield
- AHG N/A
- RIGL N/A
- EPS Growth
- AHG N/A
- RIGL N/A
- EPS
- AHG N/A
- RIGL 0.22
- Revenue
- AHG $2,414,338.00
- RIGL $157,374,000.00
- Revenue This Year
- AHG N/A
- RIGL $38.26
- Revenue Next Year
- AHG N/A
- RIGL $24.21
- P/E Ratio
- AHG N/A
- RIGL $107.48
- Revenue Growth
- AHG N/A
- RIGL 21.65
- 52 Week Low
- AHG $0.53
- RIGL $7.48
- 52 Week High
- AHG $2.90
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- AHG 49.00
- RIGL 66.77
- Support Level
- AHG $0.86
- RIGL $22.33
- Resistance Level
- AHG $0.94
- RIGL $24.58
- Average True Range (ATR)
- AHG 0.11
- RIGL 2.22
- MACD
- AHG 0.01
- RIGL 0.36
- Stochastic Oscillator
- AHG 37.36
- RIGL 64.90
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.